Modeling and Simulation of the Effect of Proton Pump Inhibitors on Magnesium Homeostasis. 1. Oral Absorption of Magnesium-Reference-Cited by-同舟云学术

Modeling and Simulation of the Effect of Proton Pump Inhibitors on Magnesium Homeostasis. 1. Oral Absorption of Magnesium

Published:2012-11-02 Issue:12 Volume:9 Page:3495-3505
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Bai Jane P. F.¹,Hausman Ethan¹,Lionberger Robert¹,Zhang Xinyuan¹

Affiliation:

1. Office of Generic Drugs, Office of Pharmaceutical Science, §Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, and †Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation, Food and Drug Administration, Rockville, Maryland, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/mp300323q

Reference59 articles.

1. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm, accessed November 2011.

2. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series

3. Severe hypomagnesaemia in long-term users of proton-pump inhibitors

4. Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

5. Hypomagnesemia Induced by Several Proton-Pump Inhibitors

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprendre, reconnaître et prendre en charge les anomalies du magnésium;Option/Bio;2023-06

2. Modeling Clinical Phenotype Variability: Consideration of Genomic Variations, Computational Methods, and Quantitative Proteomics;Journal of Pharmaceutical Sciences;2023-04

3. Proton-pump inhibitor use amongst patients with severe hypomagnesemia;Frontiers in Pharmacology;2023-01-30

4. Adverse event profiles of hypomagnesemia caused by proton pump inhibitors using the Japanese Adverse Drug Event Report (JADER) Database;PHARMAZIE;2022

5. Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan;Internal Medicine;2022-01-01